Accident Compensation Corp Sells 19,600 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Accident Compensation Corp reduced its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 18.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 84,984 shares of the company’s stock after selling 19,600 shares during the period. Accident Compensation Corp’s holdings in Teva Pharmaceutical Industries were worth $1,496,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Psagot Investment House Ltd. grew its holdings in Teva Pharmaceutical Industries by 129.9% during the third quarter. Psagot Investment House Ltd. now owns 1,510,695 shares of the company’s stock valued at $26,588,000 after purchasing an additional 853,603 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in shares of Teva Pharmaceutical Industries by 125.1% during the third quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 251,905 shares of the company’s stock worth $4,434,000 after acquiring an additional 140,000 shares in the last quarter. AMP Capital Investors Ltd lifted its position in shares of Teva Pharmaceutical Industries by 16.7% during the third quarter. AMP Capital Investors Ltd now owns 340,874 shares of the company’s stock worth $6,001,000 after acquiring an additional 48,881 shares in the last quarter. Lafayette Investments Inc. raised its position in shares of Teva Pharmaceutical Industries by 44.0% in the third quarter. Lafayette Investments Inc. now owns 14,401 shares of the company’s stock worth $253,000 after buying an additional 4,400 shares in the last quarter. Finally, Bluestein R H & Co. purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $269,000. 51.98% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on TEVA. Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 13th. BidaskClub raised Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday. Maxim Group reissued a “hold” rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Finally, UBS Group reissued a “neutral” rating and issued a $19.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Five investment analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $20.99.

Teva Pharmaceutical Industries Ltd (NYSE TEVA) traded down $0.05 on Friday, hitting $18.95. 10,551,158 shares of the company were exchanged, compared to its average volume of 27,233,690. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries Ltd has a 52 week low of $10.85 and a 52 week high of $38.31. The stock has a market cap of $19,304.00, a PE ratio of -3.18 and a beta of 0.55.

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.79%. The ex-dividend date of this dividend was Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.

TRADEMARK VIOLATION NOTICE: “Accident Compensation Corp Sells 19,600 Shares of Teva Pharmaceutical Industries Ltd (TEVA)” was published by Week Herald and is owned by of Week Herald. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://weekherald.com/2017/12/30/teva-pharmaceutical-industries-limited-teva-shares-sold-by-accident-compensation-corp.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply